Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
  • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C305/00—Esters of sulfuric acids
  • C07C305/20—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/40—Unsaturated compounds
  • C07C59/76—Unsaturated compounds containing keto groups
  • C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D209/32—Oxygen atoms
  • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
  • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
  • C07D213/18—Salts thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
  • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0003—Androstane derivatives
  • C07J1/0007—Androstane derivatives not substituted in position 17
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
  • C07J1/0003—Androstane derivatives
  • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
  • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
  • C07J53/001—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class spiro-linked
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
  • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
  • C07J71/0005—Oxygen-containing hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
  • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/02—Ortho- or ortho- and peri-condensed systems
  • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
  • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
  • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Definitions

• the present invention is in the field of pharmaceutical chemistry.
• the objective is a set of compounds which inhibit excessively activated modulate NMDA receptors, and thus protect the tissue of the central nervous system (CNS) against excessive action of glutamate.
• CNS central nervous system
• NMDA receptors are multiprotein tetrameric complexes, which are composed of two NR1 subunits and two NR2A-2D subunits that form the ion channel for positive ions ( Nature 438, 185-192 (2005 )).
• Glutamate is the major excitatory neurotransmitter in the central nervous system of mammals. Responses of the post synaptic neuron are generated during synaptic transmission via ionotropic and metabotropic glutamate receptors. N-Methyl-D-aspartate receptors (NMDA), AMPA and kainite receptors belong to the family of ionotropic glutamate receptors.
• ionotropic receptors are considered to be a key player in these processes.
• Activation of ionotropic glutamate receptors leads to changes in intracellular concentration of ions, especially calcium and sodium.
• Toxicity of higher levels of glutamate is generally associated with an increase in intracellular Ca 2+ levels.
• Glutamate-induced pathological increase in intracellular calcium is attributed to prolonged activation of ionotropic glutamate receptors. Increases in intracellular calcium may trigger a cascade of neurotoxicity.
• NMDA antagonists A number of preclinical studies have documented striking ability of NMDA antagonists to prevent an excessive action of glutamate on nerve cells and thereby reduce the impairment of the function of CNS. However, from the clinical point of view their neuroprotective potential is small. Due to the fact that NMDA receptors are one of the most widespread types of receptors in the CNS , their administration lead ussually to a number of serious side effects (e.g. distortion, induction of motoric psychoses of the schizophrenic type, etc.).
• NMDA receptors a great variety of NMDA receptors and their different distribution at synapses and in the brain and various functional states of this receptor offers great possibility of seeking for agents that selectively affect only a specific group of NMDA receptors and thereby reduce the occurrence of unanticipated and undesirable effects while maintaining the neuroprotective activity
• the level of neurosteroids temporarily after exposure to stress increases, as it is an adaptive mechanism.
• experimental models of chronic stress and depression on laboratory rodents show long-term reduced concentration of neurosteroids in the brain and in plasma, due to their reduced biosynthesis.
• neurosteroids Among well-known neurosteroids belong pregnenolone, progesterone, dehydroepiandrosterone (DHEA) and its reduced metabolite, and sulfate esters.
• DHEA dehydroepiandrosterone
• the regulation of the synthesis of neurosteroids in the CNS is not well known, but it is generally believed that the crutial is interaction of various types of cells.
• progesterone synthesis by Schwann cells in peripheral nerves is regulated by diffuse signals from neurons.
• Progesterone plays an important role in neurological recovery from traumatic brain injury and spinal cord through mechanisms involving protection against excitotoxic cell damage, lipid peroxidation and induction of specific enzymes. For example, after spinal cord transection in rats progesterone increases the number of astrocytes expressing NO synthase just above and below the site of transection.
• Neurosteroids thus significantly modulate the function of membrane receptors for neurotransmitters, in particular the GABA A receptor, NMDA receptor, and sigma1 receptors. These mechanisms are responsible for psychopharmacological effects of steroids and partly explain their anticonvulsant, anxiolytic, sedative and neuroprotective effects as well as their influence on learning and memory processes.
• pregnanolone sulfate was shown to be capable of reversing cognitive deficit in aged animals and exerting a protective effect on memory in several amnesia models of amnesia.
• Current studies have demonstrated direct effect of neurosteroids on intracellular receptors. Despite absence of direct evidence for binding of neurosteroids to corticoid receptors, they may obviously modulate their function indirectly, by interaction with protein kinases C and A, MAP-kinase or CaMKII.
• pregnanolone and pregnanolone sulfate were shown to affect microtubule-associated proteins and increase the rate of microtubule polymeration, which may in turn affect neuronal plasticity.
• Sulfated and thus amphiphilic steroid compounds generally do not penetrate the blood-brain barrier, but it was demonstrated that intravenously administered pregnanolone sulfate reach the brain ( Neuropharmacology 61, 61-68 (2011 )).
• the transport of sulfated analogs is probably mediated by active exchange mechanisms associated with so-called organic anion transport protein (OATP), which is expressed in the cells of brain tissue.
• OATP organic anion transport protein
• Inhibitors of the NMDA receptor are also some steroid derivatives and in particular reduced derivatives of progesterone. Its neuroprotective properties are also described in the patent literature ( US2012/71453 A1, 2012 ; WO2009/108804 A and WO2009/108809 ).
• WO2010003391 Anionic pregnane compounds,method for Their Producing and Use of Them
• WO2012/110010 Pregnanolone derivatives substituted in 3alpha-position with the cationic group, Their method of production, usage and pharmaceutical preparation Involving Them.
• Derivatives claimed in the present application are not pregnanolone derivatives (these compounds do not have a keto group at the C-20).
• these compounds are androstane derivatives.
• these derivatives have oxygen subtituent in a lower oxidation state (ether) than the C-20 keto group.
• the present invention relates to compounds with a protective effect on the nervous system the structure of which comprises a substituted tetradecahydrophenanthrene formula I.
• the invention also includes therapeutics composed from described compounds.
• Tetradecahydrophenanthrene skeleton can have following configuration:
• the invention thus covers amphiphilic compounds with tetradecahydrophenanthrene skeleton of general formula I, where
• Halogen is chosen from group of -F, -Cl, -Br, -I.
• Alkyl is straight or branched saturated hydrocarbon substituent, in one embodiment containing one to six carbon atoms, in another embodiment from one to four carbon atoms, selected from methyl, ethyl, n -propyl, iso -propyl, n -butyl, sec -butyl, tert -butyl, isobutyl, amyl, t -amyl, isoamyl, n -pentyl, n -hexyl and similarly; removal of one hydrogen atom from the terminal alkyl CH 3 group will form corresponding alkylene.
• Alkenyl is an unsaturated hydrocarbon substituent comprising dienes and trienes of straight or branched chains containing 2 to 6 carbon atoms, or 2 to 4 carbon atoms, preferably selected from vinyl, allyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl and similarly; removal of one hydrogen atom of the end group CH or CH 2 form the corresponding alkenylene.
• Cycloalkyl or alicyclic group is selected from saturated cyclic hydrocarbon radicals containing 3 to 6 carbon atoms, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
• the cycloalkenyl group is preferably selected from cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl.
• An aromatic group with six carbon atoms is preferably selected from phenyl.
• Heterocycle or heterocyclic group is selected from C 3 to C 6 non-aromatic cyclic hydrocarbons containing one or more heteroatoms selected from O, N and S.
• Non-aromatic hydrocarbons containing the above heteroatoms may be saturated or partially saturated monocyclic radicals.
• Abbreviation pyH means pyridinium salt of particular sulfate.
• Another object of the present invention are amphiphilic compounds with tetradecahydrophenanthrene skeleton of general formula I and the corresponding specific compounds mentioned above, for use as a medicament.
• Another aspect of the invention are also amphiphilic compounds with tetradecahydrophenanthrene skeleton of general formula I and the corresponding above-mentioned specific compounds for use in treating neuropsychiatric disorders associated with imbalances of glutamatergic neurotransmitter system, such as ischemic damage of the central nervous system, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.
• neuropsychiatric disorders associated with imbalances of glutamatergic neurotransmitter system such as ischemic damage of the central nervous system, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.
• the present invention relates also to the use of amphiphilic compounds with tetradecahydrophenanthrene skeleton of formula I for the preparation of a veterinarian or human pharmaceutical drug or composition comprising it for treating of neuropsychiatric disorders associated with imbalance of glutamatergic neurotransmitter system, such as ischemic damage to the central nervous system, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.
• neuropsychiatric disorders associated with imbalance of glutamatergic neurotransmitter system such as ischemic damage to the central nervous system, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder, and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.
• the invention also provides a pharmaceutical composition for human or veterinary use, comprising as active ingredient a compound having an amphiphilic tetradecahydrophenanthrene skeleton of general formula I or one of the above-mentioned specific amphiphilic compounds corresponding to general formula I.
• the present invention also includes the above mentioned pharmaceutical composition for treating neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and related diseases stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.
• neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and related diseases stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma.
• Mass spectra were measured on a ZAB-EQ spectrometer (at 70 eV) or LCQ Classic (Thermo Finnigan).
• aqueous hydrochloric acid solution 5%
• saturated aqueous sodium bicarbonate were used.
• Thin layer chromatography TLC was performed on plates coated with a thin layer of silica gel (ICN Biochemicals).
• Preparative column chromatography was performed on silica gel Fluka (60 microns).
• For detection of the compounds on TLC plates was used immersion in aqueous sulfuric acid solution (20 ml of 98% sulfuric acid) in methanol (250 ml) followed by heating at 300-400° C.
• Solvents were evaporated from the solution by rotary evaporation (0.25 kPa) at 40° C bath. The mobile phase for column chromatography is shown always in the experiment.
• PIN IUPAC nomenclature
• For the preparation of the active compounds tested were used de novo synthesis and modification of suitable commercially available precursors.
• Alcohol and glutaric anhydride (258 mg, 2.26 mmol) were dried at 50° C overnight. Then, dried pyridine (3 mL per 100 mg) and 4-(N,N-dimethylamino)pyridine (0.3 eq.) were added. The mixture was heated at 120° C and the progress was monitored on TLC. The reaction mixture was then cooled to room temperature, quenched by pouring reagents into water and the product extracted with chloroform. The combined organic extracts were washed with brine and dried with anhydrous magnesium sulfate. The solvents were evaporated under reduced pressure.
• n -Butyl lithium (2.5M in hexane, 1.1 eq.) was added cold dropwise to a solution of methyltriphenylphosphonium iodide (1 eq.) in dried tetrahydrofuran (30 ml per 4 g) under an inert atmosphere of nitrogen and the mixture was stirred and heated at 80° C for 2 hours. Then, a solution of compound (0.5 eq.) in dried tetrahydrofuran (minimum amount) was added. The reaction mixture was stirred at 80° C and the progress was monitored on TLC. The reaction was quenched with saturated ammonium chloride solution. The product was extracted into chloroform; the combined organic extracts were washed with brine and dried over anhydrous sodium sulfate. The solvents were evaporated under reduced pressure.
• Diketone 1 (7.36 g, 41.3 mmol), triethyl orthoformiate (7.58 ml, 45.6 mmol), and ethylene glycol (12.7 ml, 228 mmol) were dissolved in DCM (50 ml) and cooled to -10 °C. Then, trifluoromethanesulfonate (150 ml, 830 ⁇ mol) was added and the mixture was stirred at -10° C for 1 h. Then, triethylamine (200 ml, 1.43 mmol) was added and the reaction mixture was poured into saturated aqueous sodium bicarbonate solution. The product was extracted into dichloromethane (3 x 50 ml).
• Oily product 3b [ ⁇ ] D 20 +217.7 (c 0.22, CHCl 3 ).
• Example 8 4-(((2 R ,4a S ,4b S ,8a R ,10a R )-4a-Methyltetradecahydrophenanthren-2-yl)oxy)-4-oxobutanoic Acid (9)
• ester 12 (1.00 g, 2.86 mmol) and lithium aluminum hydride (2.86 mg, 8.58 mmol) in tetrahydrofuran (30 ml) was heated to reflux under an inert atmosphere of argon for 2 h.
• the excess of reagent was carefully quenched with saturated aqueous sodium sulfate; inorganic materials were removed by filtration and washed with ethyl acetate.
• the filtrate was washed with aqueous hydrochloric acid (5%), water, saturated aqueous sodium bicarbonate solution and dried over anhydrous sodium sulfate.
• the solvents were evaporated under reduced pressure.
• Example 12 (4a S ,4b S ,7 S ,8 S ,8a S ,10a R )-7-(Hydroxymethyl)-4a,7,8-trimethyldodecahydrophenanthren-2(1H)-one (14)
• Aqueous sodium hypochlorite solution (4.5%, 7.7 ml) was added to a solution of diol 13 (585 mg, 2.09 mmol) in acetic acid (18 ml).
• the reaction mixture was stirred at room temperature for 1 h, then propan-2-ol (11 ml) was added and the mixture was stirred for 30 min.
• the reaction was quenched by addition of water (20 ml), the product was extracted with chloroform (3 x 50 ml), and the combined organic extracts were washed with saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvents were evaporated and the residue flash chromatographed on silica gel (4-10% acetone in petroleum ether).
• ketone 16 400 mg, 1.37 mmol
• sodium borohydride 57 mg, 1.51 mmol
• the mixture was stirred for 1 h at 0 °C, then was warmed to room temperature and quenched with dilute hydrochloric acid (5%, 15 ml).
• the product was extracted with chloroform (3 x 20 ml), the combined organic extracts were washed with saturated aqueous sodium bicarbonate solution and dried over anhydrous magnesium sulfate.
• Example 16 Pyridinium (2 R ,4a S ,4b S ,7 S ,8 S ,8a S ,10a R )-7-(methoxymethyl)-4a,7,8-trimethyltetra-decahydrophenanthren-2-yl 2-sulfate (18)
• Example 17 4-(((2 R ,4a S ,4b S ,7 S ,8aS,10a R )-7-(Methoxymethyl)-4a,7,8-trimethyltetradecahydro-phenanthren-2-yl)oxy)-4-oxobutanoic Acid (19)
• Example 19 4-(((2 R ,4a S ,7 S ,8 S ,10a R )-7-(Methoxykarbonyl)-4a,7,8-trimethyltetradecahydro-phenanthren-2-yl)oxy)-4-oxobutanoic Acid (21)
• Example 20 Pyridinium (2 R ,4a S ,7 S ,8 S ,10a R )-7-(methoxycarbonyl)-4a,7,8-trimethyltetra-decahydrophenanthren-2-yl 2-sulfate (22)
• Example 22 Methyl (2 S ,4a S ,4b S ,7 S ,8a R ,10a R )-7-hydroxy-2,4b-dimethyl-1-(((E)-3-oxoindolin-2-yliden)methyl)-tetradecahydrophenanthren-2-carboxylate (25)
• Example 23 Methyl (2 S ,4a S ,4b S ,7 S ,8a R ,10a R )-7-acetoxy-2,4b-dimethyl-1-(((E)-3-oxoindolin-2-yliden)methyl)-tetradecahydrophenanthren-2-carboxylate (26)
• Example 24 Methyl (2 S ,4a S ,4b S ,7 S ,8a R ,10a R )-7-acetoxy-1-formyl-2,4b-dimethyltetradecahydro-phenanthren-2-carboxylate (27)
• Example 25 Methyl (2 S ,4a S ,4b S ,7 S ,8a R ,10a S )-7-acetoxy-2,4b-dimethyltetradecahydrophenanthren-2-carboxylate (28)
• Example 28 (4a S ,4b S ,7 R ,8a S ,10a R )-4a,7-Dimethyldodecahydrophenanthren-2(1H)-one (31a), (4a S ,4b S ,8a S ,10a R )-4a,7-dimethyl-3,4,4a,4b,5,8,8a,9,10,10a-decahydrophenanthren-2(1H)-one (31b) and (4a S ,4b S ,8a S ,10a R )-4a,7-dimethyl-3,4,4a,4b,5,6,8a,9,10,10a-decahydrophenanthren-2(1H)-one (31c)
• Example 29 (2 R ,4a S ,4b S ,7 R ,8a S ,10a R )-4a,7-Dimethyldodecahydrophenanthren-2-ol (32a), (2 R ,4a S ,4b S ,8a S ,10a R )-4a,7-dimethyl-3,4,4a,4b,5,8,8a,9,10,10a-decahydrophenanthren-2-ol (32b) and (2 R ,4a S ,4b S ,8a S ,10a R )-4a,7-dimethyl-3,4,4a,4b,5,6,8a,9,10,10a-decahydrophenanthren-2-ol (32c)
• Example 31 4-(((2 R ,4a S ,4b S ,7 R ,8a S ,10a R )-4a,7-Dimethyltetradecahydrophenanthren-2-yl)oxy)-4-oxobutanoic acid (34)
• Example 32 Pyridinium (2 R ,4a S ,4b S ,7 R ,8a S ,10a R )-4a,7-dimethyltetradecahydrophenanthren-2-yl 2-sulfate (35)
• Example 36 4-(((2 R ,4a S ,4b S ,7 S ,8a S ,10a R )-7-(Methoxycarbonyl)-4a,7,8a-trimethyltetradecahydro-phenanthren-2-yl)oxy)-4-oxobutanoic acid (39)
• Example 38 (4a S ,4b S ,7 S ,8a S ,10a R )-7-(Hydroxymethyl)-4a,7-dimethyldodecahydrophenanthren-2(1H)-one (41)
• Aqueous sodium hypochlorite solution (4.5 %, 1.05 ml) was added to a solution of diol 29 (80 mg, 0.30 mmol) in acetic acid (2.5 ml). The reaction mixture was stirred at room temperature for 1 h, and then was added propan-2-ol (1.5 ml) and the mixture was stirred for 30 min. The reaction was quenched by addition of water (5 mL), the product was extracted with chloroform (3 x 10 ml), and the combined organic extracts were washed with brine and dried with anhydrous magnesium sulfate.
• Example 40 (4a S ,4b S ,7 S ,8a S ,10a R )-7-(Methoxymethyl)-4a,7-dimethyldodecahydro-1H-spiro-[phenanthren-2,2'-[1,3]dioxolane] (43a)
• Example 41 (4a S ,4b S ,7 S ,8a S ,10a R )-7-(Methoxymethyl)-4a,7-dimethyldodecahydrophenanthren-2(1H)-one (43)
• ketal 43a 145 mg, 0.45 mmol
• acetone 2.5 ml
• hydrochloric acid 5%, 50 ml
• the reaction was quenched by addition of saturated aqueous sodium bicarbonate solution (10 ml), the product was extracted with ethyl acetate, and the combined organic extracts were washed with saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. Evaporation of the solvent afforded 120 mg (96%) of non-crystalline keto derivative 43: [ ⁇ ] D 20 +24.8 (c 0.42, CHCl 3 ).
• Example 43 4-(((2 R ,4a S ,4b S ,7 S ,8a S ,10a R )-7-(Methoxymethyl)-4a,7-dimethyltetradecahydro-phenanthren-2-yl)oxy)-4-oxobutanoic acid (45)
• Example 44 Pyridinium (2 R ,4a S ,4b S ,7 S ,8a S ,10a R )-7-(methoxymethyl)-4a,7-dimethyltetradecahydrophenanthren-2-yl 2-sulfate (46)
• Steroid-containing solutions were prepared from fresh solution (20 mmol.l -1 , of steroid dissolved in dimethyl sulfoxide, DMSO), which was added to the extracellular solution containing 1 mmol.l -1 glutamic acid and 10 ⁇ mol.l -1 of glycine. Identical concentrations of DMSO were added to all other extracellular solutions.
• HEK293 cells (American Type Culture Collection, ATTC No. CRL1573, Rockville, MD) were cultivated in Opti-MEM® I media (Invitrogen) with addition of 5% fetal bovine serum at 37 °C and transfected with NR1-1a/NR2B/GFP plasmids, as described in the scientific literature ( Neuroscience 151, 428-438, 2008 ). Same amounts (0.3 ⁇ g) of cDNA coding NR1, NR2 and GFP (green fluorescent protein) (pQBI 25, Takara, Japan) were mixed with 0.9 ⁇ l of Matra-A Reagent (IBA, Göttingen, Germany) and added to confluent HEK293 cells cultivated in v 24-pit cultivating plate.
• Opti-MEM® I media Invitrogen
• 5% fetal bovine serum at 37 °C
• NR1-1a/NR2B/GFP plasmids as described in the scientific literature ( Neuroscience 151, 428-438,
• NMDA receptor subunits were used for transfection: NR1-1a (GenBank accession No. U08261) and NR2B (GenBank accession No. M91562).
• HEK293 Cultured cells were used for electrophysiological investigations with a latency of 16-40 h after transfection.
• Whole-cell currents were measured by patch-clamp amplifier (Axopatch 1D; Axon Instruments, Inc. Foster City, USA) after capacitance and serial resistance ( ⁇ 10 M' ⁇ ) compensation to 80-90%.
• Agonist-induced responses were filtered to 1 kHz (8-pole Bessel filter; Frequency Devices, Haverhill, USA), digitized with sampling frequency of 5 kHz and analyzed by pClamp version 9 software (Axon Instruments, USA).
• Micropipettes made of borosilicate glass were filled with intracellular solution, containing 125 mmol.l -1 D-gluconic acid, 15 mmol.l -1 cesium chloride, 5 mmol.l -1 EGTA, 10 mmol.l -1 HEPES buffer, 3 mmol.l -1 magnesium chloride, 0.5 mmol.l -1 calcium chloride and 2 mmol.l -1 magnesium-salt of ATP (pH adjusted to 7.2 by cesium hydroxide solution).
• Extracellular solution contained 160 mmol.l -1 sodium chloride, 2.5 mmol.l -1 potassium chloride, 10 mmol.l -1 HEPES, 10 mmol.l -1 glucose, 0.2 mmol.l -1 EDTA a 0.7 mmol.l -1 calcium chloride (pH adjusted to 7.3 by sodium hydroxide solution). Glycine was added to both testing and control solution. Moreover, bicuculline (10 ⁇ mol.l -1 ) and tetrodotoxin (0.5 ⁇ m ⁇ l.l -1 ) was added to hippocampal cultures. Steroid-containing solutions were prepared from fresh solution (20 mmol.l -1 ) of steroid dissolved in dimethyl sulfoxide (DMSO). Same concentrations of DMSO were used in all extracellular solutions. Control and experimental solutions were applied via microprocessor-controlled perfusion system with approx. rate of solution exchange in areas adjacent to cells reaching -10 ms.
• DMSO dimethyl sulfoxide
• Newly synthesized analogs (8, 18, 19, 21, 22, 34, 35, 40, 128) have the same mechanism of action at the NMDA receptor as pregnanolone sulfate, but differ in their relative affinities for the NMDA receptor (see Table 2).
• mice (30-35 g) male laboratory mice, strain CD-1 from Velaz facility, Czech Republic. Mice were housed in plastic boxes with a 12-hour light cycle (lights on at 7:00 pm). Mice had free access to food and water.
• Amphiphilic steroid compounds were dissolved in a solution of 3 g (2-hydroxypropyl)- ⁇ -cyclodextrin (CDX, Sigma-Aldrich) and 157 mg of citric acid (3-hydroxy-penta-1,3,5-tricarboxylic acid, Sigma-Aldrich) in 30 ml of distilled water, the pH was adjusted to 7.4 using sodium hydroxide (NaOH, Sigma-Aldrich).
• CDX (2-hydroxypropyl)- ⁇ -cyclodextrin
• citric acid 3-hydroxy-penta-1,3,5-tricarboxylic acid, Sigma-Aldrich
• NaOH sodium hydroxide
• NMDA antagonist is memantine (Sigma-Aldrich) at a dose of 5 mg/kg in rats, ketamine (Vétoquinol) at 10 mg/kg and dizocilpine (MK-801) (Sigma-Aldrich) at a dose of 0.3 mg/kg in mice.
• memantine Sigma-Aldrich
• ketamine Vétoquinol
• MK-801 dizocilpine
• the anesthetized rats were used in operations isoflurane (3.5%, Baxter).
• excitotoxic lesion of the dorsal hippocampus was applied 0.05 mol.l -1 solution of NMDA (Sigma-Aldrich) in 0.4 mol.l -1 phosphate buffer solution prepared by mixing 356 g Na 2 HPO 4 ⁇ 12 H 2 O (M w 358.14) in 4.21 of distilled water and a solution of 62.4 g NaHPO 4 ⁇ 2H 2 O (M w 156.01) in 0.81 of distilled water.
• the pH of the resulting solution of NMDA was adjusted to 7.4 with NaOH.
• the purpose of the primary behavioral testing was quickly determined the effect of compounds on CNS dependent functions and any signs of toxicity.
• a simplified modification Irwin test was selected with respect to the behavioral profile of NMDA receptor antagonists. Mice were tested individually. The study drug was administered intraperitoneally (Table 3) at a dose of 1 mg/kg. The control group consisted of individuals that received the CDX solution or saline.
• the elevated plus maze (EPM) experiment was used to determine the effect of compounds on anxiety of animals at a dose of 1 mg/kg.
• Two control groups of animals were used to which was applied physiological saline and CDX solution, respectively.
• a noncompetitive NMDA receptor antagonist - ketamine (10 mg/kg) was given to a comparative group.
• the compounds were administered to mice intraperitoneally 30 minutes before testing in the EPM.
• mice intraperitoneally The substances at dose 0.1-100 mg/kg were administered before the test to mice intraperitoneally. As controls were used intact mice and mice that received CDX solution. Also, MK-801 (0.3 mg/kg) was used for comparison of effects of noncompetitive antagonist of NMDA receptors. From the experiment was evaluated overall track anywhere in the arena as an indicator of locomotor activity. In addition, it was judged a ten-minute segments track during each experiment. Based on these values, it was possible to determine the latency time of onset of action and changes in locomotor activity over time.
• mice were administered the relevant substance at dose 100 mg/kg to demonstrate the sedative effect, or vice versa and unexpected toxic effects of high doses of the studied compounds.
• Over time was monitored locomotor activity and possible changes characterized by tremor, ataxia, restlessness, or sedation or general anesthesia (absence of response to stimuli, decreased muscle tone).
• This assay was used to monitor the antidepressant effect. Animals float 6 minutes in acrylic cylinder in water at 24 °C. A period of immobility is evaluated. The reduction is a manifestation of anti-depressant properties of drugs.
• Aversive motivated memory test was evaluated on the basis of latency input into the preferred, but unpleasant sensation associated with delivery device.
• the anxiety rate was evaluated based on the number of entries into the open arms and the total time spent in the open arms of the maze. It has been showed that after administration androstane glutamate at 1 mg/kg significantly increased both parameters as compared with both control groups (saline and CDX solution, respectively), which demonstrates the anxiolytic effects of androstane glutamate. The highest values of both monitored parameters of all the test compounds were achieved after administration androstane glutamate at 1 mg/kg.
• the antidepressant effect was studied similarly in a forced swimming test.
• the efficacy was evaluated as a decrease flotation in mice after administration of the studied compounds, as reference substance was used ketamine, which in accordance with the literature showed antidepressant effect.
• ketamine which in accordance with the literature showed antidepressant effect.
• the compounds of the present invention are industrially manufacturable and usable for the treatment of many diseases of the central nervous system such as: hypoxic and ischemic damage of CNS, stroke and other pathological changes caused hyperexcitation; neurodegenerative changes and disorders; affective disorders, depression, post-traumatic stress disorder, and diseases related to stress; schizophrenia and other psychotic disorders; pain, hyperalgesia, disturbance in the perception of pain; addiction; multiple sclerosis and other autoimmune diseases; epilepsy and other disorders manifesting hyperplazic seizures and changes in the central nervous system, tumors of the central nervous system, including gliomas.
• diseases of the central nervous system such as: hypoxic and ischemic damage of CNS, stroke and other pathological changes caused hyperexcitation; neurodegenerative changes and disorders; affective disorders, depression, post-traumatic stress disorder, and diseases related to stress; schizophrenia and other psychotic disorders; pain, hyperalgesia, disturbance in the perception of pain; addiction; multiple sclerosis and other autoimmune diseases; epilepsy and other disorders manifesting hyperplazic seizures

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Anesthesiology (AREA)
• Hospice & Palliative Care (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Psychology (AREA)
• Heart & Thoracic Surgery (AREA)
• Addiction (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (4)

Related Parent Applications (2)

Publications (2)

Family

ID=54140190

Family Applications (2)

Family Applications Before (1)

Country Status (7)

Families Citing this family (3)

Family Cites Families (14)

• 2014
  • 2014-08-26 CZ CZ2014-575A patent/CZ2014575A3/cs unknown
• 2015
  • 2015-08-25 US US15/506,318 patent/US10017535B2/en active Active
  • 2015-08-25 CA CA3013725A patent/CA3013725C/en active Active
  • 2015-08-25 EP EP15763482.5A patent/EP3186267B1/en active Active
  • 2015-08-25 JP JP2017511948A patent/JP6437636B2/ja active Active
  • 2015-08-25 EP EP17183215.7A patent/EP3260462B1/en not_active Not-in-force
  • 2015-08-25 CA CA2957906A patent/CA2957906C/en active Active
  • 2015-08-25 WO PCT/CZ2015/000096 patent/WO2016029888A1/en active Application Filing
  • 2015-08-25 AU AU2015309371A patent/AU2015309371B2/en active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events